Literature DB >> 8572211

Somatostatin receptors.

T Reisine1.   

Abstract

Somatostatin induces its biological actions by activating a family of receptor subtypes. The recent cloning of five somatostatin receptor subtypes has led to the development of subtype-selective agonists. These compounds are revealing distinct functions of the individual receptor subtypes. Mutagenesis studies have revealed domains of several of the receptors involved in specific recognition of somatostatin analogues. Molecular modeling of both of these ligand-binding domains and the constrained somatostatin analogues that they interact with may lead to the development of nonpeptide somatostatin drugs that could be useful in the treatment of tumors and various metabolic, gastrointestinal, and central nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8572211     DOI: 10.1152/ajpgi.1995.269.6.G813

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

Review 1.  Octreoscan radioreceptor imaging.

Authors:  Aart J van der Lely; Wouter W de Herder; Eric P Krenning; Dik J Kwekkeboom
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

2.  Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro.

Authors:  Manoj Kumar; Zheng-Ren Liu; Laxmi Thapa; Qing Chang; Da-Yu Wang; Ren-Yi Qin
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

3.  The somatostatinergic system in the mammalian cochlea.

Authors:  Vesna Radojevic; Claudia Hanusek; Cristian Setz; Yves Brand; Josef P Kapfhammer; Daniel Bodmer
Journal:  BMC Neurosci       Date:  2011-09-06       Impact factor: 3.288

4.  Role of somatostatin receptor-2 in gentamicin-induced auditory hair cell loss in the Mammalian inner ear.

Authors:  Yves Brand; Vesna Radojevic; Michael Sung; Eric Wei; Cristian Setz; Andrea Glutz; Katharina Leitmeyer; Daniel Bodmer
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.